Ixazomib (Ninlaro) Dosing Schedule, Missed Dose Management and Cycle Planning in 28‑Day Regimen

　　Ixazomib(Ninlaro)is an oral proteasome inhibitor used in the treatment of multiple myeloma.Patient eligibility shall follow the drug label and physician’s clinical assessment.The standard regimen follows a 28‑day cycle:the medicine is taken once on Day 1,Day 8 and Day 15 of each cycle.The period starting from Day 22 serves as a rest interval to allow recovery of bone marrow and gastrointestinal tissues.This dosing rhythm is established by clinical studies;patients should not shorten or extend the interval on their own,as a single missed dose will disrupt drug exposure across the whole cycle.If dosing must be delayed for medical examinations,try to maintain a 7‑day interval between doses to avoid drug accumulation.Inpatients can coordinate administration timing with healthcare staff to avoid conflicts with tests.Any adjustment to the dosing date must preserve the original interval.

　　The protocol does not specify which weekday the doses should fall on.Patients may choose an easy‑to‑remember weekday and keep it consistent throughout treatment.Scheduling Cycle Day 1 on the same day as clinic visits is a practical option,facilitating blood tests and reducing weekday travel.Setting three reminders on a mobile calendar is more reliable than paper notes.Marking dosing dates on the medication box and filling in the next due date when collecting prescriptions helps prevent missed doses.

　　In combination regimens,dexamethasone is usually given once weekly on the same day as ixazomib to reduce clinic visits.Dexamethasone is preferably taken in the morning to minimise insomnia.Ixazomib can be taken with or without food,but taking it 1 hour before or 2 hours after meals helps maintain stable absorption;the exact sequence of combined dosing follows the physician’s instructions.If dexamethasone causes stomach discomfort,a gastric mucosal protective agent may be added under medical advice.Blood glucose should be monitored during combination therapy,especially for diabetic patients.Significant fatigue after dosing should be reported at the next visit for evaluation and potential adjustment.

　　If a scheduled dose coincides with travel,discuss rescheduling to an adjacent date with the physician in advance while maintaining a 7‑day interval.If a dose is missed and more than 2 days remain before the next planned dose,contact the physician to confirm whether a make‑up dose is appropriate.Do not take doses on two consecutive days to compensate for a missed dose,as this increases gastrointestinal and haematological toxicity.Before travelling,confirm whether blood tests can be performed at the destination;if not,complete relevant tests in advance.Any change to the dosing date should be recorded to support accurate cycle calculation for subsequent cycles.

　　After the rest week of the 28‑day cycle,Day 1 of the next cycle must be recalculated rather than simply carried over from the previous month.If blood counts have not recovered by the end of a cycle,dosing will be postponed;the physician‑confirmed date shall prevail.Recording the three dosing dates of each cycle in a follow‑up log helps avoid cumulative calculation errors.When blood counts recover slowly,physicians may extend the rest week instead of reducing the dose.No catch‑up doses are needed during the rest week,and the next cycle must not be started early.New or worsening numbness in hands or feet should be reported before the next dose for neuropathy grading and assessment.